Faculty, Staff and Student Publications
Publication Date
1-1-2023
Journal
WIREs Nanomedicine and Nanobiotechnology
DOI
10.1002/wnan.1867
PMID
36308008
Abstract
Radioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lung, esophagus, pancreas, prostate, and soft tissue sarcoma. Supported by decades of preclinical investigation and recent randomized trial data establishing clinical activity, these agents are poised to influence future multimodality treatment paradigms involving radiotherapy. Although the physical interactions between NPs and ionizing radiation are well characterized, less is known about how these agents modify the tumor microenvironment, particularly regarding tumor immunogenicity. In this review, we describe the key multidisciplinary considerations related to radiation, surgery, immunology, and pathology for designing radioenhancing NP clinical trials. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
Keywords
Male, Humans, Nanomedicine, Neoplasms, Lung, Nanoparticles, Tumor Microenvironment, dose enhancement, metal nanoparticles, nanoparticle, radiosensitizer
Published Open-Access
yes
Recommended Citation
DuRoss, Allison N; Phan, Jack; Lazar, Alexander J; et al., "Radiotherapy Reimagined: Integrating Nanomedicines Into Radiotherapy Clinical Trials" (2023). Faculty, Staff and Student Publications. 4648.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4648
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Nanomedicine Commons, Oncology Commons